[Pharmacologic limitation of the size of the myocardial infarction (excluding thrombolysis)].
Several pharmacological agents possess cardio-protective properties. Some of these agents have been evaluated in the context of the limitation of the size of the myocardial infarction. In this study, controlled randomised trials evaluated the effects of a solution of glucose-insulin-potassium (GIK), hyaluronidase, nitrate derivatives, calcium antagonists and beta-blockers administered during the first few hours following acute myocardial infarction. Despite promising results, we do not yet have any proof of the effectiveness of the GIK solution, hyaluronidase or nitrate derivatives. Nifedipine appears to be devoid of any effect and other calcium antagonists are currently under investigation. The numerous trials have been performed with beta-blockers generally support their beneficial effect on the limitation of the size of the infarction, which is usually accompanied by a reduction in the mid and long term mortality. They are therefore recommended in this indication and their practical use is discussed.
Zannad
F
F
Gilgenkrantz
J M
JM
Royer
R J
RJ
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D009566:Nitrates / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D007328:Insulin; D009566:Nitrates; C030396:glucose-insulin-potassium cardioplegic solution; D006821:Hyaluronoglucosaminidase; D005947:Glucose; D011188:Potassium
Limitation pharmacologique de la taille de l'infarctus du myocarde (thrombolyse exclue).